NTRA Stock Overview
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Natera, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.11 |
| 52 Week High | US$59.75 |
| 52 Week Low | US$30.46 |
| Beta | 1.21 |
| 1 Month Change | -10.23% |
| 3 Month Change | -16.58% |
| 1 Year Change | 32.85% |
| 3 Year Change | 8.67% |
| 5 Year Change | 276.58% |
| Change since IPO | 107.17% |
Recent News & Updates
Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?
May 16
Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement
Apr 18Recent updates
Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?
May 16Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement
Apr 18Natera: Cracks In The Bearish Trade
Oct 10Natera gains after publication of data on transplant rejection assessment test
Oct 04Natera (NASDAQ:NTRA) Has Debt But No Earnings; Should You Worry?
Sep 13Medicare extends coverage of Natera's Signatera test to muscle invasive bladder cancer
Jul 18Nothing Compelling About Natera
Jun 24Is Natera (NASDAQ:NTRA) Weighed On By Its Debt Load?
May 30Despite Lacking Profits Natera (NASDAQ:NTRA) Seems To Be On Top Of Its Debt
Feb 21Natera: Standout Buy In Diagnostic Testing Materials, Now Seen By Market-Makers
Dec 24Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?
Nov 08Shareholder Returns
| NTRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.4% | -2.2% | 1.0% |
| 1Y | 32.9% | 11.4% | -0.2% |
Return vs Industry: NTRA exceeded the US Biotechs industry which returned 10% over the past year.
Return vs Market: NTRA exceeded the US Market which returned -0.1% over the past year.
Price Volatility
| NTRA volatility | |
|---|---|
| NTRA Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: NTRA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 2,988 | Steve Chapman | https://www.natera.com |
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company’s products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test.
Natera, Inc. Fundamentals Summary
| NTRA fundamental statistics | |
|---|---|
| Market Cap | US$5.38b |
| Earnings (TTM) | -US$546.14m |
| Revenue (TTM) | US$867.85m |
6.2x
P/S Ratio-9.9x
P/E RatioIs NTRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTRA income statement (TTM) | |
|---|---|
| Revenue | US$867.85m |
| Cost of Revenue | US$501.17m |
| Gross Profit | US$366.68m |
| Other Expenses | US$912.82m |
| Earnings | -US$546.14m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.78 |
| Gross Margin | 42.25% |
| Net Profit Margin | -62.93% |
| Debt/Equity Ratio | 55.7% |
How did NTRA perform over the long term?
See historical performance and comparison